Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy

Benjamin D. Horne; Petra A. Lenzini; Mia Wadelius; Andrea L. Jorgensen; Stephen E. Kimmel; Paul M. Ridker; Niclas Eriksson; Jeffrey L. Anderson; Munir Pirmohamed; Nita A. Limdi; Robert C. Pendleton; Gwendolyn A. Mcmillin; James K. Burmester; Daniel Kurnik; C. Michael Stein; Michael D. Caldwell; Charles S. Eby; Anders Rane; Jonatan D. Lindh; Jae Gook Shin; Ho Sook Kim; Pantep Angchaisuksiri; Robert J. Glynn; Kathryn E. Kronquist; John F. Carlquist; Gloria R. Grice; Robert L. Barrack; Juan Li; Brian F. Gage

doi:10.1160/TH11-06-0388

Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy

Benjamin D. Horne, Petra A. Lenzini, Mia Wadelius, Andrea L. Jorgensen, Stephen E. Kimmel, Paul M. Ridker, Niclas Eriksson, Jeffrey L. Anderson, Munir Pirmohamed, Nita A. Limdi, Robert C. Pendleton, Gwendolyn A. Mcmillin, James K. Burmester, Daniel Kurnik, C. Michael Stein, Michael D. Caldwell, Charles S. Eby, Anders Rane, Jonatan D. Lindh, Jae Gook ShinHo Sook Kim, Pantep Angchaisuksiri, Robert J. Glynn, Kathryn E. Kronquist, John F. Carlquist, Gloria R. Grice, Robert L. Barrack, Juan Li, Brian F. Gage

Office of the Dean of Pharmacy

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	232-240
Number of pages	9
Journal	Thrombosis and Haemostasis
Volume	107
Issue number	2
DOIs	https://doi.org/10.1160/TH11-06-0388
State	Published - 2012

ASJC Scopus Subject Areas

Hematology

Keywords

CYP2C9
Pharmacogenetic
VKORC1
Warfarin

Access to Document

10.1160/TH11-06-0388

Cite this

Horne, B. D., Lenzini, P. A., Wadelius, M., Jorgensen, A. L., Kimmel, S. E., Ridker, P. M., Eriksson, N., Anderson, J. L., Pirmohamed, M., Limdi, N. A., Pendleton, R. C., Mcmillin, G. A., Burmester, J. K., Kurnik, D., Michael Stein, C., Caldwell, M. D., Eby, C. S., Rane, A., Lindh, J. D., ... Gage, B. F. (2012). Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thrombosis and Haemostasis, 107(2), 232-240. https://doi.org/10.1160/TH11-06-0388

Horne, BD, Lenzini, PA, Wadelius, M, Jorgensen, AL, Kimmel, SE, Ridker, PM, Eriksson, N, Anderson, JL, Pirmohamed, M, Limdi, NA, Pendleton, RC, Mcmillin, GA, Burmester, JK, Kurnik, D, Michael Stein, C, Caldwell, MD, Eby, CS, Rane, A, Lindh, JD, Shin, JG, Kim, HS, Angchaisuksiri, P, Glynn, RJ, Kronquist, KE, Carlquist, JF, Grice, GR, Barrack, RL, Li, J & Gage, BF 2012, 'Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy', Thrombosis and Haemostasis, vol. 107, no. 2, pp. 232-240. https://doi.org/10.1160/TH11-06-0388

@article{80f020071f224df89f737901a3715da9,

title = "Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy",

keywords = "CYP2C9, Pharmacogenetic, VKORC1, Warfarin",

author = "Horne, \{Benjamin D.\} and Lenzini, \{Petra A.\} and Mia Wadelius and Jorgensen, \{Andrea L.\} and Kimmel, \{Stephen E.\} and Ridker, \{Paul M.\} and Niclas Eriksson and Anderson, \{Jeffrey L.\} and Munir Pirmohamed and Limdi, \{Nita A.\} and Pendleton, \{Robert C.\} and Mcmillin, \{Gwendolyn A.\} and Burmester, \{James K.\} and Daniel Kurnik and \{Michael Stein\}, C. and Caldwell, \{Michael D.\} and Eby, \{Charles S.\} and Anders Rane and Lindh, \{Jonatan D.\} and Shin, \{Jae Gook\} and Kim, \{Ho Sook\} and Pantep Angchaisuksiri and Glynn, \{Robert J.\} and Kronquist, \{Kathryn E.\} and Carlquist, \{John F.\} and Grice, \{Gloria R.\} and Barrack, \{Robert L.\} and Juan Li and Gage, \{Brian F.\}",

year = "2012",

doi = "10.1160/TH11-06-0388",

language = "English",

volume = "107",

pages = "232--240",

journal = "Thrombosis and Haemostasis",

issn = "0340-6245",

number = "2",

}

TY - JOUR

T1 - Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy

AU - Horne, Benjamin D.

AU - Lenzini, Petra A.

AU - Wadelius, Mia

AU - Jorgensen, Andrea L.

AU - Kimmel, Stephen E.

AU - Ridker, Paul M.

AU - Eriksson, Niclas

AU - Anderson, Jeffrey L.

AU - Pirmohamed, Munir

AU - Limdi, Nita A.

AU - Pendleton, Robert C.

AU - Mcmillin, Gwendolyn A.

AU - Burmester, James K.

AU - Kurnik, Daniel

AU - Michael Stein, C.

AU - Caldwell, Michael D.

AU - Eby, Charles S.

AU - Rane, Anders

AU - Lindh, Jonatan D.

AU - Shin, Jae Gook

AU - Kim, Ho Sook

AU - Angchaisuksiri, Pantep

AU - Glynn, Robert J.

AU - Kronquist, Kathryn E.

AU - Carlquist, John F.

AU - Grice, Gloria R.

AU - Barrack, Robert L.

AU - Li, Juan

AU - Gage, Brian F.

PY - 2012

Y1 - 2012

KW - CYP2C9

KW - Pharmacogenetic

KW - VKORC1

KW - Warfarin

UR - https://www.scopus.com/pages/publications/84863012482

UR - https://www.scopus.com/inward/citedby.url?scp=84863012482&partnerID=8YFLogxK

U2 - 10.1160/TH11-06-0388

DO - 10.1160/TH11-06-0388

M3 - Article

C2 - 22186998

AN - SCOPUS:84863012482

SN - 0340-6245

VL - 107

SP - 232

EP - 240

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

IS - 2

ER -

Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy

ASJC Scopus Subject Areas

Keywords

Access to Document

Other files and links

Cite this